A PHASE 2/3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF ORAL BREPOCITINIB IN ADULTS WITH CUTANEOUS SARCOIDOSIS

Registry ID

PVT-2201-203

Source registry

HEALTH_CANADA

Status

Pending

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

PRIOVANT THERAPEUTICS, INC

Last update

2026-07-07

Conditions

• SARCOIDOSIS

View on source registry